A selection of CRISPR therapies which are in Phase II and Phase III clinical trials
| NCT04933825 | EdiGene Inc | EdiGene Inc | ET-02 | Phase II | Relapsed or Refractory B-cell Malignancy(non-Hodgkins lymphoma/acute lymphoblastic leukemia) |
|---|---|---|---|---|---|
| NCT06041620 | Shanghai Vitalgen BioPharma Co Ltd | Institute of Hematology & Blood Diseases Hospital | VGB-Ex01 | Phase II | Beta Thalassaemia, Thalassemia |
| NCT06128629 | Regeneron Pharmaceuticals Inc | Intellia Therapeutics Inc | NTLA-2001 | Phase III | Amyloidosis, Familial Amyloid Cardiomyopathy |
| NCT05309733 | Vor BioPharma Inc | Vor BioPharma Inc | VOR33 | Phase II | Acute Myelocytic Leukemia |
